PROCEPT BioRobotics Corporation (PRCT)
| Market Cap | 1.30B |
| Revenue (ttm) | 308.05M |
| Net Income (ttm) | -95.57M |
| Shares Out | 56.39M |
| EPS (ttm) | -1.72 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,220,884 |
| Open | 24.21 |
| Previous Close | 24.09 |
| Day's Range | 22.52 - 24.45 |
| 52-Week Range | 19.35 - 66.85 |
| Beta | 0.93 |
| Analysts | Buy |
| Price Target | 35.44 (+53.95%) |
| Earnings Date | Apr 29, 2026 |
About PRCT
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hype... [Read more]
Financial Performance
In 2025, PROCEPT BioRobotics's revenue was $308.05 million, an increase of 37.22% compared to the previous year's $224.50 million. Losses were -$95.57 million, 4.55% more than in 2024.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for PRCT stock is "Buy." The 12-month stock price target is $35.44, which is an increase of 53.95% from the latest price.
News
PROCEPT BioRobotics® to Report First Quarter 2026 Financial Results on April 29, 2026
SAN JOSE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transf...
EAU Guidelines Upgrade Aquablation® Therapy to Strong Surgical Recommendation for BPH
Updated European Association of Urology guidelines reflect growing clinical evidence supporting Aquablation therapy in the surgical treatment of benign prostatic hyperplasia Updated European Associati...
PROCEPT BioRobotics® Announces International Launch of the HYDROS® Robotic System, Expanding Global Access to AI-Enabled Aquablation® Therapy
SAN JOSE, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT), today announced the international expansion of the HYDROS Robotic System, the company's next-generation platfor...
PRCT Investors Have Opportunity to Join PROCEPT BioRobotics Corporation Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)---- $PRCT--PRCT Investors Have Opportunity to Join PROCEPT BioRobotics Corporation Fraud Investigation with the Schall Law Firm.
PROCEPT BioRobotics Transcript: TD Cowen 46th Annual Health Care Conference
New organizational structures and launch teams are driving faster system adoption and improved utilization. Inventory management has stabilized, and a replacement strategy for legacy systems is being developed. HYDROS systems show higher usage, and market expansion efforts target both procedure conversion and patient awareness.
Ademi LLP Investigates Claims of Securities Fraud against PROCEPT BioRobotics Corporation
MILWAUKEE, Feb. 26, 2026 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against PROCEPT BioRobotics (NASDAQ: PRCT). The investigation results from inaccurate statements PR...
PROCEPT BioRobotics Transcript: Investor Day 2026
Significant growth is targeted through increased procedure volume, higher ASPs, and organizational realignment, with a focus on profitability and leveraging clinical differentiation. Expansion into prostate cancer and targeted marketing are expected to drive future upside, while 2026–2027 guidance projects robust revenue and margin improvement.
PROCEPT BioRobotics® Hosts 2026 Investor Day to Detail Multi-year Financial Outlook and Strategic Plan for Long-Term Growth
NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative s...
PROCEPT BioRobotics Stock Hits 52-Week Low - Here's Why
PROCEPT BioRobotics Corp. (NASDAQ: PRCT) shares are down during Thursday's premarket session following the company's recent financial results and updates on its revenue guidance.
PROCEPT BioRobotics Earnings Call Transcript: Q4 2025
Q4 2025 saw 69% procedure growth but lower revenue due to inventory destocking and pricing discipline, with handpiece ASP rising 5%. 2026 guidance calls for 27%-33% revenue growth, higher margins, and positive EBITDA in Q4, despite short-term disruption from commercial realignment.
PROCEPT BioRobotics Reports Fourth Quarter 2025 Financial Results and Updates 2026 Revenue Guidance
SAN JOSE, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transfo...
PROCEPT BioRobotics® Announces Updated Dates for 4Q25 Earnings Conference Call and Investor Day
SAN JOSE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transfor...
PROCEPT BioRobotics® to Attend the TD Cowen 46th Annual Health Care Conference and the 2026 Leerink Global Healthcare Conference
SAN JOSE, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solut...
PROCEPT BioRobotics® to Host 4Q25 Earnings Conference Call on February 24, 2026, and Investor Day on February 25, 2026, in New York City
SAN JOSE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transfor...
PROCEPT BioRobotics Transcript: Piper Sandler 37th Annual Healthcare Conference
Management is prioritizing procedure growth and inventory optimization, with new launch processes and dedicated teams to improve utilization. Strong capital sales and a focus on upgrading to the HYDROS platform are expected to drive future growth, while reimbursement remains favorable and patient-centric messaging is set to expand.
PROCEPT BioRobotics® to Present at Upcoming 37th Annual Piper Sandler Healthcare Conference on December 2, 2025
SAN JOSE, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solut...
PROCEPT BioRobotics Earnings Call Transcript: Q3 2025
Q3 2025 revenue grew 43% year-over-year, driven by strong U.S. and international sales, with gross margin expanding to 64.8%. FY2025 guidance remains robust, with continued investments in commercial execution, utilization, and international growth, despite some procedural and inventory headwinds.
PROCEPT BioRobotics Reports Third Quarter 2025 Financial Results and Issues 2026 Revenue Guidance
SAN JOSE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transfo...
PROCEPT BioRobotics® to Report Third Quarter 2025 Financial Results on November 4, 2025
SAN JOSE, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transfo...
PROCEPT BioRobotics Earnings Call Transcript: Q2 2025
Q2 2025 revenue grew 48% year-over-year, with strong U.S. and international performance, gross margin expansion, and improved net loss. Full-year guidance was raised, leadership transitions are underway, and the HYDROS system launch and CPT code upgrade support future growth.
PROCEPT BioRobotics Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
SAN JOSE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transfo...
PROCEPT BioRobotics® President and CEO Dr. Reza Zadno to Retire, Company Appoints Larry L. Wood as New President and CEO
SAN JOSE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (“the Company”), a surgical robotics company focused on advancing patient care by developing transformative solut...
Ambulatory Surgery Center Completes WATER IV Trial Procedures for Prostate Cancer with Aquablation® Therapy
SAN JOSE, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company dedicated to advancing patient care through transformat...
PROCEPT BioRobotics® to Report Second Quarter 2025 Financial Results on August 6, 2025
SAN JOSE, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transfo...
Aquablation® Therapy's Assigned Category I Code in 2026 Medicare Proposed Physician Fee Schedule
SAN JOSE, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company dedicated to advancing patient care through transformat...